|
Characteristics
|
n (%)
|
|---|
|
Total, N
|
368(100)
|
|
Tumor type
|
|
GBC
|
73 (19.8)
|
|
ICC
|
74 (20.1)
|
|
ECC
|
221 (60.0)
|
|
Age (years)
|
|
≤ 60
|
155 (42.1)
|
|
> 60
|
213 (57.9)
|
|
Sex
|
|
Female
|
168 (45.7)
|
|
Male
|
200 (54.3)
|
|
BMI at diagnosis, kg/m2
|
|
< 18.5
|
19 (5.2)
|
|
18.5–22.9
|
128 (34.8)
|
|
≥ 23
|
177 (48.1)
|
|
NA
|
44 (12.0)
|
|
Alcohol
|
|
Yes
|
90 (24.5)
|
|
No
|
278 (75.5)
|
|
Fatty liver
|
|
Yes
|
27 (7.3)
|
|
No
|
341 (92.7)
|
|
Jaundice
|
|
Yes
|
219 (59.5)
|
|
No
|
149 (40.5)
|
|
Tumor size, cm
|
|
D ≤ 2
|
180 (50.6)
|
|
2 < D ≤ 3
|
85 (23.1)
|
|
3 < D ≤ 4
|
35 (9.5)
|
|
D > 4
|
56 (15.2)
|
|
NA
|
12 (3.3)
|
|
Lymph node metastasis
|
|
Yes
|
122 (33.2)
|
|
No
|
246 (66.8)
|
|
Extrahepatic involvement
|
|
Yes
|
252 (68.5)
|
|
No
|
116 (31.5)
|
|
Intrahepatic involvement
|
|
Yes
|
111 (30.2)
|
|
No
|
257 (69.8)
|
|
Gallbladder involvement
|
|
Yes
|
91 (24.7)
|
|
No
|
277 (75.3)
|
|
AJCC 8th TNM stage
|
|
I
|
133 (36.1)
|
|
II
|
120 (32.6)
|
|
III
|
115 (31.3)
|
|
Tumor differentiation
|
|
Undifferentiation
|
2 (0.5)
|
|
Low
|
36 (9.8)
|
|
Low-moderate
|
98 (26.6)
|
|
Moderate
|
102 (27.7)
|
|
Moderate-high
|
28 (7.6)
|
|
High
|
102 (27.7)
|
|
Radical cure
|
|
Yes
|
232 (63.0)
|
|
No
|
136 (37.0)
|
|
R0
|
|
Yes
|
248 (67.4)
|
|
No
|
120 (32.6)
|
|
TC level, mmol/L
|
|
≤ 7.28
|
301 (81.8)
|
|
> 7.28
|
67 (18.2)
|
|
TG level, mmol/L
|
|
≤ 3.14
|
301 (81.8)
|
|
> 3.14
|
67 (18.2)
|
|
HDL level, mmol/L
|
|
≤ 0.95
|
205 (55.7)
|
|
> 0.95
|
163 (44.3)
|
|
LDL level, mmol/L
|
|
≤ 1.96
|
41 (11.1)
|
|
> 1.96
|
327 (88.9)
|
|
TC/HDL
|
|
≤ 10.08
|
256 (69.6)
|
|
> 10.08
|
112 (30.4)
|
|
TG/HDL
|
|
≤ 4.16
|
258 (70.1)
|
|
> 4.16
|
110 (29.9)
|
|
ApoA1 level, g/L
|
|
≤ 1.11
|
166 (45.1)
|
|
> 1.11
|
150 (40.8)
|
|
NA
|
52 (14.1)
|
|
ApoB level, g/L
|
|
≤ 0.90
|
210 (57.1)
|
|
> 0.90
|
105 (28.5)
|
|
NA
|
53 (14.4)
|
|
Lipoprotein level, mg/L
|
|
≤ 72
|
152 (41.3)
|
|
> 72
|
118 (32.1)
|
|
NA
|
98 (26.6)
|
|
Albumin level, g/L
|
|
≤ 35
|
59 (16.0)
|
|
> 35
|
305 (82.9)
|
|
NA
|
4 (1.1)
|
|
ALT level, U/L
|
|
≤ 40
|
116 (31.5)
|
|
> 40
|
252 (68.5)
|
|
AST level, U/L
|
|
≤ 40
|
130 (35.3)
|
|
> 40
|
233 (63.3)
|
|
NA
|
5 (1.4)
|
|
GGT level, U/L
|
|
≤ 45
|
72 (19.5)
|
|
> 45
|
291 (79.1)
|
|
NA
|
5 (1.4)
|
|
ALP level, U/L
|
|
≤ 135
|
121 (32.9)
|
|
> 135
|
242 (65.7)
|
|
NA
|
5 (1.4)
|
|
LDH level, U/L
|
|
≤ 250
|
300 (81.5)
|
|
> 250
|
61 (16.6)
|
|
NA
|
7 (1.9)
|
|
TBIL level, umol/L
|
|
≤ 17.1
|
113 (30.7)
|
|
> 17.1
|
255 (69.3)
|
|
CA199 level, U/mL
|
|
≤ 37
|
94 (25.5)
|
|
> 37
|
263 (71.5)
|
|
NA
|
11 (3.0)
|
|
Overall survival, months
|
21.9 (11.0–39.0)
|
- ALP Alkaline phosphatase, ALT Alanine aminotransferase, ApoA1 ApolipoproteinA-1, APOB Apolipoprotein B, AST Aspartate aminotransferase, BMI Body mass index, CA199 Carbohydrate antigen 199, CC Cholangiocarcinoma, D maximum diameter of tumor, ECC Extrahepatic cholangiocarcinoma, GBC Gallbladder cancer, GGT Gamma-glutamyl transpeptidase, HDL High-density lipoprotein, ICC Intrahepatic cholangiocarcinoma, LDH Lactate dehydrogenase, LDL low-density lipoprotein, NA Not accessible, R0 Histologically negative surgical margin, TBIL Total bilirubin, TC Total cholesterol, TG Triglycerides
